Dual block with lapatinib and trastuzumab versus single agent trastuzumab combined with chemotherapy as neoadjuvant treatment of HER2-positive breast cancer: a meta-analysis of randomized trials
M Clavarezza, M Puntoni, Alessandra Gennari, L Paleari, N Provinciali, M D'amico, A DeCensi
Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review
Fingerprint
Entra nei temi di ricerca di 'Dual block with lapatinib and trastuzumab versus single agent trastuzumab combined with chemotherapy as neoadjuvant treatment of HER2-positive breast cancer: a meta-analysis of randomized trials'. Insieme formano una fingerprint unica.